Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Assessment of CSF Shunt Flow and Headaches With a Thermal Measurement Device

NCT06996600 · tracked via the Priya Life Science USA tracker
Phase
Not applicable
Started
2025-05-02
Last updated
2025-05-30

Condition(s) studied

Hydrocephalus

Investigational drug(s) / intervention(s)

wireless thermal anisotropy measurement device

wireless thermal anisotropy measurement device: Wireless wearable thermal anisotropy measurement device designed for use at home

Study summary

This study evaluates the performance of a device for non-invasively assessing cerebrospinal fluid (CSF) shunt flow over multiple measurements performed by a study subject during headache and non-headache periods.

Eligibility

Sex
ALL
Min age
6 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Existing ventriculoperitoneal CSF shunt 2. Subject experiencing ongoing headaches including at least 15 headache days per month for the past 3 months 3. Region of intact skin overlying an unambiguously identifiable palpable chronically indwelling ventricular shunt which crosses the clavicle and is appropriate in size for application of the study device 4. Available for remote and in-person follow-up during the 30-day measurement period 5. Signed informed consent by subject or a parent, legal guardian, health care agent, or surrogate decision maker (according to local statutes) 6. Subject or caregiver is able to clearly communicate and document information and shunt symptoms in English 7. Subject is at least 6 years old but not more than 80 years old Exclusion Criteria: 1. Presence of more than one distal shunt catheter in the study device measurement region 2. Shunt is not palpable due to depth or depth of shunt where the device will be placed is greater than 4 mm per ultrasound evaluation 3. Presence of an interfering open wound or edema in the study device measurement region 4. Subject-reported history of serious adverse skin reactions to silicone-based adhesives 5. Investigator judges that the subject is likely to be lost to follow-up due to unavailability or clinical outcome being unobtainable 6. Investigator judges that the subject is unlikely to successfully take reliable measurements at home 7. Investigator judges that the subject/subject's caretaker would not be able to successfully place the device without assistance 8. Use of the study device would interfere with standard patient care, or emergency surgery that cannot be delayed, or participation in the study will interfere with, or be detrimental to, administration of optimal healthcare to the subject 9. Prior enrollment in this study 10. Participation in any other investigational procedural, pharmaceutical, and/or device study that may influence the collection of valid data under this study

Primary outcome measure(s)

  • Correlation Between Study Device Flow Measurement and Subject-reported Headaches — 30 days
    Exploratory analysis to determine the relationship between headaches (subject-reported headache and non-headache periods) and measured flow. Data will be analyzed using the Point-Biserial Correlation Coefficient between headaches periods (headache and non-headache periods) and thermal flow score (flow score derived from algorithm analysis of raw thermal data)

Trial sites (1)

FacilityCityRegionStatus
Rhaeos, Inc Chicago Illinois Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06996600 on ClinicalTrials.gov ↗ ← All trials in the USA